Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da C. Domenichini

Correlazione tra dati istologici e profili immunofenotipici in pazienti affetti da mieloma multiplo in differente tipo di trattamento
Correlation between bone marrow histology and plasma cell immunophenotyping in patients with multiple myeloma under various treatments
<p>The diagnostic and response criteria of multiple myeloma have been established by the International Myeloma Working Group. Although bone marrow morphology represents the gold standard both in the diagnostic and in the post-therapy practice, the role of multiparameter immunophenotyping by flow cytometry is currently gaining importance. The rapidity and high sensitivity to distinguish normal plasma cells from the pathological ones make this technique a precious tool, especially in defining the therapeutical response and in detecting minimal residual disease. We compared 92 simultaneous patterns of plasma cell immunophenotype and bone marrow morphology of multiple myeloma, after treatment with either chemoterapy alone or high-dose therapy with autologous or allogeneic stem cell transplantation. The aim was to determine the percentage of agreement of the two techniques in establishing the response to treatment. Discordant results were obtained in 6 cases, in which flow cytometry was able to correctly establish the degree of response to therapy. Our study shows the utility of using flow cytometry in response assessment in patients treated for multiple myeloma, with particular reference to patients in apparent complete remission and patients with oligoclonal bands observed after high-dose therapy.</p>
Biochimica Clinica ; 41(1) 072-078
Contributi scientifici - Scientific papers
 
Impiego della citofluorimetria multiparametrica nella valutazione della risposta alla terapia in pazienti con macroglobulinemia di Waldenström
Use of multiparameter flow cytometry in the evaluation of treatment effectiveness in Waldenström macroglobulinemia
Biochimica Clinica ; 40(3) 285-286
Lettere all'Editore - Letters to the Editor
 
Armonizzazione in Medicina di Laboratorio
Harmonization in Laboratory Medicine
F. Ceriotti  |  M. Panteghini  |  A. Tosetto  |  V. Valentini  |  L. Politi  |  R. Rolla  |  T. Guastafierro  |  T. Köken  |  E. Capoluongo  |  C. Mazzaccara  |  V. D'Argenio  |  V. D'Argenio  |  G. Lippi  |  M. Plebani  |  D. Giavarina  |  M. Berardi  |   A survey on sample matrix and preanalytical management in clinical laboratories  |  D. Bozzato  |  M. Panteghini  |  F. Braga  |  G. Gessoni  |  M. Montagnana  |  N. Doğan  |  M. Barberis  |  M. Barberis  |  A. Marchetti  |  F. Borrillo  |  L. Bonfanti  |  P.M. Ness  |  G. Messeri  |  S. Nannini  |  E. Fiorio  |  L. Crinò  |  M. A. V. Willrich  |  A. Modenese  |  M. Berardi  |  G. Nordera  |  R. Danesi  |  M. Locatelli  |  M. Savoia  |  S. Bernardini  |  C. Domenichini  |  P. Pradella  |  A. D'Avolio  | 
Biochimica Clinica ; 39(6) 546-547
Editoriale - Editorial
 
Monitoraggio molecolare di Isocitrato Deidrogenasi 2 in paziente con Leucemia Mieloide Acuta recidivata
Molecular monitoring of Isocitrate Dehydrogenase 2 in a patient with relapsed Acute Myeloid Leukemia
<p>Isocitrate Dehydrogenase 2 (IDH2) mutations are reported in about 20% of Acute Myeloid Leukemia (AML) and they are promising Minimal/Measurable Residual Disease (MRD) molecular markers because of the possible therapy whit the inhibitor Enasidenib. A man with a diagnosis of AML, negative for the common molecular markers, resulted in complete remission (CR) only after three induction cycles. The patient underwent a transplant procedure but after 7 months a relapse was observed. We retrospectively studied the status of IDH2 mutation in this patient which was positive at diagnosis (29%), after two induction cycles and at the allogeneic transplantation (2%). In the next follow-up, both WT1 and IDH2 were normal. After 3 months, when the patient was in CR and WT1 was still normal, IDH2 resulted 0.12%. After further 2 months, the patient clinically relapsed; at that time, WT1 was very high and IDH2 was 7.8%. In this case, IDH2 monitoring by Droplet Digital PCR (ddPCR) predicted relapse two months before WT1 levels and clinical evidence.</p>
Biochimica Clinica ; 17(1)
Casi Clinici - Case Report